Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2B | P41595 | 4/20 | 0.43 |
| ▸ | HTR3A | P46098 | 4/20 | 0.43 |
| ▸ | HTR4 | Q13639 | 4/20 | 0.43 |
| ▸ | HTR2C | P28335 | 3/20 | 0.43 |
| ▸ | HTR7 | P34969 | 2/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.39 |
| ▸ | SRC | P12931 | 2/20 | 0.37 |
| ▸ | HTR2A | P28223 | 2/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21062987 | 1.00 | HTR2B (0.43) | HTR2BHTR3AHTR4HTR2CHTR7 | |
| SCHEMBL29996483 | 0.89 | HTR2B (0.39) | HTR2BHTR3AHTR4HTR2CHTR7 | |
| SCHEMBL21062896 | 0.89 | HTR2B (0.39) | HTR2BHTR3AHTR4HTR2CHTR7 | |
| SCHEMBL21099542 | 0.88 | HTR2B (0.39) | HTR2BHTR3AHTR4HTR2CHTR7 | |
| SCHEMBL21062906 | 0.87 | ADORA2A (0.37) | HTR2BHTR3AHTR4HTR2CHTR7 | |
| SCHEMBL29995387 | 0.87 | ADORA2A (0.37) | HTR2BHTR3AHTR4HTR2CHTR7 | |
| SCHEMBL29996110 | 0.87 | CCR3 (0.46) | HTR2BHTR3AHTR4HTR2CHTR7 | |
| SCHEMBL21063195 | 0.87 | CCR3 (0.46) | HTR2BHTR3AHTR4HTR2CHTR7 | |
| SCHEMBL21063102 | 0.86 | DRD4 (0.38) | HTR2BHTR3AHTR4HTR2CHTR7 | |
| SCHEMBL29996292 | 0.86 | DRD4 (0.38) | HTR2BHTR3AHTR4HTR2CHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3723754-B1 | IMIDAZO [1,2-C] QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | MERCK SHARP & DOHME LLC (US) | 2026-05-13 | — | — | EP | disclosed |
| US-11498923-B2 | Substituted imidazo[1,2-c]quinazolines as A2A antagonists | MERCK SHARP & DOHME LLC (US) | 2022-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11498923-B2 | Substituted imidazo[1,2-c]quinazolines as A2A antagonists | ADORA2A, ADORA3, ADORA1 | HTR2B 46/4885HTR3A 8/4885HTR4 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.